The Biological Basis of Histologic Transformation
- PMID: 32586580
- DOI: 10.1016/j.hoc.2020.02.010
The Biological Basis of Histologic Transformation
Abstract
Histologic transformation of follicular lymphoma remains the leading cause of follicular lymphoma-related mortality in the rituximab era. Both the diverse timing of transformation and heterogeneity in associated genomic events suggest that histologic transformation may itself comprise distinct disease entities. Successive indolent and transformation episodes occur by divergent clonal evolution from an inferred common progenitor cell, representing a potential therapeutic target. Existing biological knowledge largely pre-dates anti-CD20 therapy, and further prospective validation is essential. Inclusion of transformation cases in clinical trials incorporating biomarker discovery, and an integrated understanding of the genetic and microenvironmental factors underpinning transformation, may unearth renewed clinical opportunities.
Keywords: Follicular; Genomics; Lymphoma; Transformation.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Our research is supported by Cancer Research UK (15968 awarded to J. Fitzgibbon, 22742 awarded to J. Okosun) and Bloodwise program grant [15002] through the Precision Medicine for Aggressive Lymphoma (PMAL) consortium. E.A. Kumar is in receipt of fellowship funding from The Medical College of Saint Bartholomew’s Hospital Trust. J. Fitzgibbon declares grants from Epizyme and personal fees from Roche, Gilead and Epizyme.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
